ZD-6126 AstraZeneca.
AstraZeneca is developing ZD-6126, one of the ANG-400 series of vascular-targeting and tubulin-binding agents under license from Angiogene Pharmaceuticals Ltd, for the potential treatment of cancer.
Soltau
Jens
J
Tumor Biology Center, Department of Medical Oncology, Breisacher Strasse 117, 79106 Freiburg, Germany. drevs@tumorbio.uni-freiburg.de
Drevs
Joachim
J
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009943:Organophosphorus Compounds / Q000737:chemistry / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; C455219:N-acetylcochinol-O-phosphate; D009943:Organophosphorus Compounds